HAD-C 106
HADe009-A
General#
Cell Line |
|
| hPSCreg Name | HADe009-A |
| Alternative name(s) |
HAD-C 106
|
| Cell line type | Human embryonic stem cell (hESC) |
| Last update | 22nd May 2019 |
| User feedback | |
Provider |
|
| Generator | Hadassah University Hospital (HAD) |
| Owner | Hadassah University Hospital (HAD) |
| Distributors | |
| Derivation country | Israel |
External Databases |
|
| Cellosaurus | CVCL_B862 |
| NIHhESC | NIHhESC-11-0125 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Clinical: allowed
Commercial: allowed
|
| Subclones | |
Donor Information#
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Family history | No diseases known |
| Is the medical history available upon request? | Medical history known |
| Is clinical information available? | No health conditions known |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Ethics#
| Was the embryo established purely for research purposes? | No |
| Have both parents consented to the use of the embryo for ESC derivation? | Yes |
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | Additional documents sent sep. |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | IRB |
| Approval number | 33-26-07.02 |
hESC Derivation#
| Date of derivation | 2009-01-16 |
| Embryo stage | Blastula with ICM and Trophoblast |
| Supernumerary embryos from IVF treatment? |
Yes
Separation of research and IVF treatment?
Yes |
| PGD Embryo? |
No |
| Expansion status |
4
|
| ICM morphology |
A
|
| Trophectoderm morphology |
b
|
| Cell isolation | Laser |
| Cell seeding | Isolated ICM |
| Derived under xeno-free conditions? |
Yes |
| Derivation under GMP? |
Yes |
| Available as clinical grade? |
Yes |
Culture Conditions#
| Surface coating | Gelatin |
| Feeder cells |
umbilical cord fibroblasts |
| Passage method |
Enzymatically
TrypLE
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: DMEM
Main protein source: Human Serum Serum concentration: 20 % |
Characterisation#
Differentiation Potency
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
|
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
XY Normal
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.